𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Preemptive therapy for cytomegalovirus

✍ Scribed by Nina Singh; Victor L. Yu

Book ID
102472792
Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
39 KB
Volume
12
Category
Article
ISSN
1527-6465

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Valganciclovir as preemptive therapy for
Valganciclovir as preemptive therapy for cytomegalovirus in cytomegalovirus-seronegative liver transplant recipients of cytomegalovirus-seropositive donor allografts
✍ Nina Singh; Cheryl Wannstedt; Lois Keyes; Debra Mayher; Lisa Tickerhoof; Mohamed πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 82 KB

The efficacy of valganciclovir as preemptive therapy for the prevention of cytomegalovirus (CMV) disease and its impact on indirect sequelae of CMV were assessed in recipient-negative/donor-positive (RΟͺ/DΟ©) liver transplant recipients. Of 187 consecutive liver transplant recipients at our institutio

Antiviral drugs for cytomegalovirus in t
Antiviral drugs for cytomegalovirus in transplant recipients: advantages of preemptive therapy
✍ Nina Singh πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 106 KB

## Abstract Currently available, potent antiviral agents have proven highly effective for the prevention of CMV disease during the time that prophylaxis is employed. However, late‐onset CMV disease, occurring in 5–18% of the patients, has emerged as a significant complication in organ transplant re